Skip to main content
Erschienen in: Drug Safety 10/2010

01.10.2010 | Editorial

Reflections on Attribution and Decisions in Pharmacovigilance

verfasst von: Ola Caster, I. Ralph Edwards

Erschienen in: Drug Safety | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Excerpt

In general, a causal relationship depends upon the nature and amount of evidence supporting an attribution hypothesis, such that ‘A causes B’. A can be a sufficient cause of B, meaning that A is always followed by B; or a necessary cause, meaning that B cannot occur without being preceded by A; or both. These deterministic concepts are not relevant to pharmacovigilance. No drug is a sufficient cause of an adverse effect, and there are no examples of necessary causes either. The trigger to modern pharmacovigilance, thalidomide, has come close to being considered a necessary cause of phocomelia, but this is not true. Phocomelia is very rare in the absence of thalidomide but not vanishingly so; x-irradiation is one example of another cause.[1] This example is illuminating also because it shows that the definition of the hypothesis is critical: one must be sure one knows what A and B are. In this case we have used the terms phocomelia, ectromelia, amelia and limb-reduction disorder loosely as synonyms when in reality they are overlapping hierarchical entities. …
Literatur
1.
Zurück zum Zitat Galloway JL, Delgado I, Ros MA, et al. A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature 2009; 460(7253): 400–4PubMed Galloway JL, Delgado I, Ros MA, et al. A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature 2009; 460(7253): 400–4PubMed
2.
Zurück zum Zitat Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006 Dec; 333(7581): 1267–9PubMedCrossRef Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006 Dec; 333(7581): 1267–9PubMedCrossRef
3.
Zurück zum Zitat Hill AB. The environment and disease: association or casuation? Proc R Soc Med 1965; 58(5): 295–300PubMed Hill AB. The environment and disease: association or casuation? Proc R Soc Med 1965; 58(5): 295–300PubMed
4.
Zurück zum Zitat Hauben M, Aronson JK. Defining ‘signal’ and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32(2): 99–110PubMedCrossRef Hauben M, Aronson JK. Defining ‘signal’ and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009; 32(2): 99–110PubMedCrossRef
6.
Zurück zum Zitat Edwards IR, Lindquist M, Wiholm BE, et al. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990 Jul; 336(8708): 156–8PubMedCrossRef Edwards IR, Lindquist M, Wiholm BE, et al. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990 Jul; 336(8708): 156–8PubMedCrossRef
7.
Zurück zum Zitat Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30(5): 367–73PubMedCrossRef Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30(5): 367–73PubMedCrossRef
8.
Zurück zum Zitat Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan–Feb; 12(1): 17–29PubMedCrossRef Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan–Feb; 12(1): 17–29PubMedCrossRef
9.
Zurück zum Zitat Bowdler J, editor. Effective communications in pharmacovigilance: the Erice report. Uppsala: The Uppsala Monitoring Centre, 1998 Bowdler J, editor. Effective communications in pharmacovigilance: the Erice report. Uppsala: The Uppsala Monitoring Centre, 1998
Metadaten
Titel
Reflections on Attribution and Decisions in Pharmacovigilance
verfasst von
Ola Caster
I. Ralph Edwards
Publikationsdatum
01.10.2010
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 10/2010
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/11532460-000000000-00000

Weitere Artikel der Ausgabe 10/2010

Drug Safety 10/2010 Zur Ausgabe